abstract |
The present invention relates to triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors of the formula (I) wherein said ring X is a 5-7 membered heterocyclic ring, and wherein A, Y, B, G and W are as defined in the specification; and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders. |